NexGard Combo spot on for Cats up to 2.5 kg (5.5lb), (1 pipette)
NexGard Combo is intended for the control and prevention of infection with fleas, mites (including ear mites) and helminths in cats. The drug is convenient because it simultaneously affects 12! types of feline parasites. It is recommended to be used when the animal suffers from external and internal parasites at the same time or there is a reasonable suspicion of such a problem.
The drug NexGard Combo kills ticks and protects against re-infection from one month to 5 weeks (depending on the species), and kills fleas so quickly that they do not have time to lay eggs. NexGard Combo is just as cruel to worms. An amazing drug of the new generation will cleanse the cat’s body of most types of parasites in just one dose!
Three active substances in the composition of the drug effectively fight not only with adult individuals of parasites, but also with their larvae. Cats must be treated for parasites, otherwise they multiply very quickly and in critical quantities can cause irreparable damage to the pet’s health. NexGard Combo can be used not only for adult cats, but also for kittens in the period of active growth: the use is allowed for animals 8 weeks from birth and weighing from 0.8 kg.
NexGard Combo is used for the treatment of tapeworms, gastrointestinal helminths, it is also effective in the treatment of infections caused by pulmonary helminths, and is used for the prevention of heartworm disease.
Simultaneous infection of animals with different types of parasites is a big problem, and NexGard Combo is a reliable helper in the fight against it.
Advantages and features:
broad-spectrum antiparasitic drug: effectively fights endo- and ectoparasites;
recommended for use when affected by several types of parasites;
can be used for kittens over 8 weeks old;
is a preventive measure against heartworm disease;
the drug is available in 2 dosages;
simple and convenient form of application;
drug safe for animals and effective against parasites.
NexGard Combo, point application solution for cats weighing < 2.5 kg
NexGard Combo, point application solution for cats weighing 2.5-7.5 kg
Each dose of the applicator contains:
Active substances: esafoxolaner, eprinomectin, praziquantel
NexGard dosage unit volume Combo (ml):
Esafoxolaner (mg) 3.60
Eprinomectin (mg) 1.20
Praziquantel (mg) 24.90
Butylhydroxytoluene (E321) 1 mg/ml.
External use only.
Transparent solution from colorless to light yellow or light brown color.
For cats infected or at risk of simultaneous infection with cestodes, nematodes and ectoparasites.
The veterinary medicinal product is indicated exclusively for simultaneous exposure to all three groups.
Treatment of flea infestations (Ctenocephalides felis). One treatment provides immediate and sustained flea killing activity for one month.
The product may be part of a treatment strategy for flea allergy dermatitis (DAP).
Treatment of tick infestation. One treatment provides immediate and sustained tick control against Ixodes scapularis for one month and against Ixodes ricinus for five weeks.
Treatment of flatworms (Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis, Joyeuxiella pasqualei and Joyeuxiella fuhrmanni).
Prevention of cardiac dirofilariasis (Dirofilaria immitis) for a month.
Treatment of gastrointestinal nematode infections (L3, L4 larvae and adults of Toxocara cati, L4 larvae and adults of Ancyclostoma tubaeforme and Ancyclostoma ceylanicum and adults of Toxascaris leonina and Ancyclostoma braziliense).
Treatment of feline lungworm infections (L4 larvae and adults of Troglostrongylus brevior).
Treatment of bladder infections (Capillaria plica).
Do not use in cases of hypersensitivity to the active substances or any of the excipients.
In clinical studies, hypersalivation, diarrhea, transient skin reactions at the application site (local alopecia, pruritus), anorexia, lethargy, and vomiting were rarely observed shortly after administration. Most reactions are mild, short-lived and self-resolving.
The frequency of adverse reactions is determined using the following convention:
Very common (more than 1 in 10 treated animals have an adverse reaction)
Common (more than 1 but less than 10 animals per 100 treated animals)
Uncommon (more than 1 but less than 10 animals per 1000 treated animals)
Rare (more than 1 but less than 10 animals per 10,000 animals treated)
Very rare (less than 1 animal per 10,000 animals treated, including isolated reports).
If you notice any side effects, even those not already listed in this leaflet, or if you think that the medicine has not worked, tell your veterinarian.
Target species: cats
Method of application:
For local application to the skin (spot injection).
The minimum recommended doses are 1.44 mg esafoxolaner, 0.48 mg eprinomectin and 10 mg praziquantel per kg body weight.
Recommendations for use:
Use an applicator of the appropriate volume for the cat’s weight (0.3 or 0.9 ml).
Use scissors to cut the package along the dotted line.
Remove the applicator from the package and hold it with the tip facing up.
Slowly pull the piston back, turn and remove the cap.
Prepare the area on the animal’s nape (a place that is hard to reach for licking the drug) for applying the drug by moving the cat’s fur and exposing the skin area.
Place the tip of the applicator on the skin and apply the entire contents directly to the skin in one place.
The product must be applied to dry skin in a place where the cat cannot lick it off. In long-haired breeds, special care must be taken to apply the product directly to the skin and not the wool to ensure optimum effectiveness.
For the treatment of flea and/or tick and/or ringworm infestations and concomitant treatment of gastrointestinal and/or pulmonary and/or urinary nematodes and cestodes, a single dose of the drug should be used. The necessity and frequency of treatment must be in accordance with the recommendations of the veterinarian and take into account the local epidemiological situation and the lifestyle of the animal (for example, if it has access to the street).
Endemic areas without cardiovascular heartworm disease: Cats that are not at constant risk of heartworm infection should be treated according to a program recommended by the veterinarian, adapted to each individual situation of re-infection/re-infection. Otherwise, a product with a shorter spectrum of action should be used, which provides the correct treatment of the relevant parasites.
Cardiovascular heartworm endemic areas: cats living in areas endemic for cardiovascular helminths can be treated at monthly intervals to ensure adequate heartworm prevention and treatment of possible re-infection with cestodes. Otherwise, it is necessary to use a product with a shorter spectrum of action to continue the treatment. Prevention of cardiovascular helminths, heartworms by killing Dirofilaria immitis larvae should be started within 1 month after the first contact with mosquitoes and continue until 1 month after the last contact with mosquitoes.
Ear tick infestation: In the case of an ear infestation, request a new veterinary examination 4 weeks after treatment to decide if additional treatment with a lower-spectrum product is needed.
Special precautions for storage:
Keep out of the reach of children.
Store the unused applicator in the original package in order to protect from light.
Used material should be disposed of immediately as waste.
Do not use this veterinary product after the expiry date stated on the package.
Special precautions after use:
Avoid shampooing the animal for the next 2 days after administration, as the effectiveness of the product in this case has not been tested.
Ticks and fleas must start feeding on the cat to be exposed to esafoxolaner, so the risk of arthropod transmission cannot be ruled out.
Cats living in areas endemic for heartworms, or those who have traveled to such areas, may be infected with adult heartworms. Although the drug can be safely administered to cats infected with adult heartworms, the therapeutic effect against adult heartworms Dirofilaria immitis has not been established. Therefore, it is recommended that all cats 6 months of age and older living in heartworm-endemic areas be tested for adult heartworm infection prior to treatment with a heartworm preventative.
Infection with flatworms can recur if intermediate hosts such as fleas, mice, etc. are not controlled.
Parasite resistance to a certain class of antiparasitic drugs can develop as a result of repeated use of a compound of that class over a long period of time. Therefore, epidemiological information on the current susceptibility of the target species should be taken into account to limit the possibility of future resistance selection.
To reduce re-infection with the appearance of new fleas, it is recommended to treat all cats in the house. Any other species of animals that live in the same house should be treated with the product intended for them.
Fleas at any stage of their development can infest the cat’s litter box, its usual resting places, such as carpets and upholstered furniture. In case of a large infestation and before applying control measures, these areas should be treated with an appropriate agent and vacuumed regularly.
Special precautions for use in animals:
For spot application only. Do not enter by injection, do not enter orally or by other means of administration. Avoid contact with the cat’s eyes. In case of accidental contact with the eyes, immediately rinse the area around the eyes with clean water. If eye irritation persists, seek veterinary advice.
It is very important that the application of the veterinary medicinal product is carried out on the skin in an area where the cat cannot lick the product on the back of the head between the shoulder blades. Make sure the animals do not lick each other until the treated area is no longer visible. Oral administration of the veterinary medicinal product has been reported to cause hypersalivation in cats.
The safety of the veterinary medicinal product has not been tested in kittens under 8 weeks of age. The product is not intended for cats weighing less than 0.8 kg and/or less than 8 weeks of age.
The veterinary medicinal product should be used exclusively against confirmed mixed infections or when cats are at significant risk of such mixed infections with ectoparasites and nematodes (including for the prevention of cardiovascular heartworm disease) and when simultaneous treatment against cestodes is indicated. In the absence of risk of co-infestation, an antiparasitic agent with a shorter spectrum of action should be used as the first line of treatment.
The reason for prescribing and the frequency of use of this product should take into account the individual needs of the cat based on clinical assessment, the animal’s lifestyle and the epidemiological situation (including zoonotic risk, if applicable) in order to make a decision on use. exclusively in situations of infection or risk of combined infection.
The veterinary medicine cannot be used on other cats without prior consultation with a veterinarian.
Repeated courses of treatment should be limited to specific individual situations (see recommendations for the use of treatment in “Recommendations for correct use”) with a minimum interval between courses of treatment of 4 weeks. Safety has not been evaluated for more than 6 months, so a maximum of 6 consecutive months of treatment within a 12-month period is recommended.
Echinococcosis poses a danger to humans and is one of the diseases controlled by the World Organization for Animal Health. With echinococcosis, it is necessary to observe special rules of treatment and observation and protection of persons. Parasitological experts or institutes should be consulted.
Special precautions to be taken by persons administering veterinary medicinal products to animals:
Do not smoke, drink or eat while handling the product.
Wash hands immediately after use.
Used applicators should be disposed of immediately and kept out of the sight or reach of children.
Avoid contact of fingers with the contents of the applicator. If this happens, wash with soap and water. This veterinary medicinal product may cause eye irritation, which in exceptional cases may be severe. In case of accidental contact with eyes, rinse immediately and thoroughly with water. Remove contact lenses, if worn, for the first 5 minutes and continue rinsing. Seek medical advice and show the leaflet or product label to the doctor.
Before touching the application area, make sure that the area where the product was applied is no longer visible. Children should not play with treated animals until the application site is no longer visible, and it is recommended that recently treated animals do not sleep with their owners, especially children. It is recommended to treat animals in the evening to reduce contact with humans after treatment.
People with known hypersensitivity to esafoxolaner, eprinomectin or praziquantel or to any of the excipients should not use this veterinary medicinal product.
Because fetotoxic and teratogenic effects have been described in laboratory animals after significant daily exposure to glycerol formal, pregnant women should wear gloves during administration to avoid direct contact with the product.
Pregnancy and lactation:
The safety of the veterinary medicinal product during pregnancy and lactation has not been established. Since fetotoxic and teratogenic effects have been described in laboratory animals following significant daily exposure to glycerol formal, it should only be used in accordance with a risk/use assessment by a veterinarian.
Safety was evaluated in healthy kittens 8 weeks of age and older, administered 5 times the maximum recommended dose and up to 6 times at 4-week intervals. At a dose 3 times higher than the maximum recommended dose, no adverse reactions were observed. At a dose 5 times the maximum recommended dose, one severe neurological adverse reaction (ataxia, disorientation, apathy, tremor, hypothermia, and pupil dilation) was observed after the third treatment, which was reversible after washing the affected area.
In some animals, when the maximum 5-fold recommended dose was administered, dark red subcutaneous areas were observed at the injection site.
Registration certificate:Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein Germany
Packaging : 1 dose (applicator)
Holder of the registration certificate: Boehringer Ingelheim International GmbH, Germany
Location of production facilities: France, Brazil